img click

slideshow

About Us


arrow Mission
arrow Company Overview
arrow Management
arrow Board of Directors
arrow Investors

Company Overview


Escape Therapeutics, Inc. is an early stage biotechnology company focused on accelerating the commercial availability of allogeneic stem cell therapies by solving the key translational hurdle preventing their clinical utility - immune mismatch and subsequent donor rejection.

Invented by Escape's founder Dr. Hantash while at Stanford University, our platform technology represents a significant potential breakthrough that can revolutionize the treatment of numerous medical diseases that require cell and/or organ replacement such as type I diabetes, Parkinson's, and leukemia, amongst others. Escape's innovative technology allows for the creation of the world's first allogeneic, "off-the-shelf" therapy capable of being used in any patient irrespective of their HLA profile without the need for adjunctive immunosuppression, HLA matching, or autologous sourcing.

2010 Escape Therapeutics, Inc. All rights reserved.

Website design by Sylvia Do & Chris Nye

img